Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-γ1 in acute myeloid leukemia cells
Open Access
- 16 September 2004
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 18 (11) , 1914-1917
- https://doi.org/10.1038/sj.leu.2403461
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicinBlood, 2004
- Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)Oncogene, 2003
- ABCG2 (BCRP) expression in normal and malignant hematopoietic cellsHematological Oncology, 2003
- Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cellsBlood, 2003
- Antibody-targeted chemotherapy with immunoconjugates of calicheamicinCurrent Opinion in Pharmacology, 2003
- Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2001